GlassScriptPhysician profile
Kyra J Vineyard
NPI 1225005895
$6,867.70
in general payments reported to CMS, 2019-2025
34 companies · $907 in 2025
The $907 reported for 2025 was more than what 84% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,255 · 2020: $863 · 2021: $1,176 · 2022: $742 · 2023: $905 · 2024: $1,019 · 2025: $907.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,831.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,831.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,028.78 | 2019-2024 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $864.60 | 2019-2024 | Mounjaro, Zepbound, Reyvow |
| Novo Nordisk INC | $722.37 | 2019-2025 | Wegovy, Ozempic |
| Bayer Healthcare Pharmaceuticals INC. | $655.24 | 2023-2025 | |
| Abbvie INC. | $482.48 | 2021-2025 | Vraylar |
| Teva Pharmaceuticals USA, INC. | $303.48 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $263.54 | 2021-2025 | Jardiance |
| Sunovion Pharmaceuticals INC. | $237.78 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $229.72 | 2020-2024 | Trintellix |
| Allergan, INC. | $210.09 | 2019-2020 | |
| Pfizer INC. | $202.36 | 2023-2025 | |
| Idorsia Pharmaceuticals US INC | $172.95 | 2023-2025 | Quviviq, Quviviq |
| Paratek Pharmaceuticals, INC. | $158.49 | 2025 | Nuzyra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $145.41 | 2020-2024 | Xifaxan |
| Glaxosmithkline, LLC. | $142.82 | 2021 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $142.59 | 2021-2024 | Vyepti |
| Amarin Pharma, INC. | $136.46 | 2019 | |
| Corium, LLC | $100.71 | 2023-2024 | Azstarys |
| Supernus Pharmaceuticals, INC. | $99.18 | 2019-2024 | Qelbree, Qelbree |
| Amgen INC. | $80.14 | 2020-2021 | |
| Abbott Laboratories | $71.20 | 2022-2025 | Freestyle Libre 3 |
| Azurity Pharmaceuticals, INC. | $62.89 | 2023-2025 | Azmiro, Horizant, Edarbi |
| Biohaven Pharmaceuticals, INC. | $59.22 | 2021 | |
| Eisai INC. | $56.06 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $47.84 | 2020-2021 | |
| Axsome Therapeutics, INC. | $43.80 | 2023-2024 | Auvelity |
| Genentech USA, INC. | $29.72 | 2020-2022 | |
| Exact Sciences Corporation | $27.68 | 2024 | Cologuard Collection Kit |
| Sanofi-Aventis U.S. LLC | $19.23 | 2021 | |
| Ibsa Pharma INC. | $15.70 | 2020 | |
| Arbor Pharmaceuticals, INC. | $14.91 | 2021 | |
| Alfasigma USA, INC. | $13.55 | 2020 | |
| Currax Pharmaceuticals LLC | $13.53 | 2025 | Contrave |
| Adlon Therapeutics L.P. | $13.18 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kyra Vineyard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.